Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 15/20 | 0.62 |
| ▸ | CCNT1 | O60563 | 14/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.58 |
| ▸ | CDK1 | P06493 | 2/20 | 0.58 |
| ▸ | CDK4 | P11802 | 2/20 | 0.58 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.58 |
| ▸ | CCND1 | P24385 | 2/20 | 0.58 |
| ▸ | ABL2 | P42684 | 2/20 | 0.58 |
| ▸ | GSK3A | P49840 | 2/20 | 0.58 |
| ▸ | CDK7 | P50613 | 2/20 | 0.58 |
| ▸ | CCNH | P51946 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4098710 | 0.86 | CDK9 (0.64) | CDK9CCNT1CYP1A2USP2ALDH1A1 | |
| SCHEMBL4103869 | 0.86 | CDK9 (0.82) | CDK9CCNT1CYP1A2USP2ALDH1A1 | |
| SCHEMBL4101912 | 0.86 | CDK9 (0.67) | CDK9CCNT1CYP1A2USP2ALDH1A1 | |
| SCHEMBL4104620 | 0.85 | USP2 (0.68) | CDK9CCNT1CYP1A2USP2ALDH1A1 | |
| SCHEMBL4103782 | 0.84 | CDK9 (0.62) | CDK9CCNT1CYP1A2USP2ALDH1A1 | |
| SCHEMBL4104610 | 0.84 | USP2 (0.69) | CDK9CCNT1CYP1A2USP2ALDH1A1 | |
| SCHEMBL4101901 | 0.84 | CDK9 (0.61) | CDK9CCNT1CYP1A2USP2ALDH1A1 | |
| SCHEMBL4098113 | 0.83 | USP2 (0.63) | CDK9CCNT1CYP1A2USP2ALDH1A1 | |
| SCHEMBL4109370 | 0.82 | CYP1A2 (0.62) | CDK9CCNT1CYP1A2USP2ALDH1A1 | |
| SCHEMBL4109311 | 0.82 | USP2 (0.61) | CDK9CCNT1CYP1A2USP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150368209-A1 | 4-Pyrimidinylamino-benzenesulfonamide derivatives and their use for the inhibition of polo-like kinase 1 (PLK1) for the treatment of cancer and their use for the treatment of bacterial infections | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) | 2015-12-24 | — | — | US | disclosed |
| US-20150368209-A1 | 4-Pyrimidinylamino-benzenesulfonamide derivatives and their use for the inhibition of polo-like kinase 1 (PLK1) for the treatment of cancer and their use for the treatment of bacterial infections | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) | 2015-12-24 | — | — | US | disclosed |
| US-20150368209-A1 | 4-Pyrimidinylamino-benzenesulfonamide derivatives and their use for the inhibition of polo-like kinase 1 (PLK1) for the treatment of cancer and their use for the treatment of bacterial infections | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368209-A1 | 4-Pyrimidinylamino-benzenesulfonamide derivatives and their use for the inhibition of polo-like kinase 1 (PLK1) for the treatment of cancer and their use for the treatment of bacterial infections | PLK1, PLK2, PLK4 | CDK9 83/4885CCNT1 523/4885CYP1A2 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.